Int J Chron Obstruct Pulmon Dis:需要住院治疗的AECOPD患者QTc延长的意义

2018-08-12 符校魁 罂粟花

QT间期延长与扭转性室速风险增加和心血管死亡有关。COPD急性加重期(AECOPD)具有高心脏病发病率和死亡率的风险,目前尚不清楚QT延长在COPD急性加重期中的发生率和临床相关性。

背景与目的:QT间期延长与扭转性室速风险增加和血管死亡有关。COPD急性加重期(AECOPD)具有高心脏病发病率和死亡率的风险,目前尚不清楚QT延长在COPD急性加重期中的发生率和临床相关性。

方法:方法设计了一种双横断面研究策略。一项回顾性研究评估了140名需要住院的AECOPD患者,其中一半患者入院时心电图QTc延长。进行单因素多变量分析以确定相关因素; Kaplan-Meier和Cox回归分析评估预后意义。 一项前瞻性研究评估了180名需要住院治疗的急性呼吸道疾病患者,以确定入院时延长的QTc是否代表AECOPD特异性表现,并调查住院期间QTc持续时间的变化。

结果:回顾性分析显示:心电图上的低钾血症,心肌肌钙蛋白T和心电异常及QTc延长显着且独立地相关。 QTc延长与全因死亡率升高有关(HR 2.698(95%CI 1.032-7.055),p = 0.043),然而,校正年龄、FEV1和心肌肌钙蛋白T的这种关联不再显着。前瞻性分析显示:QTc 在被诊断患有AECOPD,肺癌,肺部感染或其他急性肺病的1/3患者中观察到延长,但是在AECOPD中没有更普遍。患有COPD的患者在住院期间后QTc持续时间显着下降。

结论:延长的QTc是AECOPD期间潜在血管疾病的标志物。它不是COPD特异表现,而是在肺病急性期需要紧急住院时才常被发现。

原始出处

Van Oekelen O, Vermeersch K, Everaerts S, et al. Significance of prolonged QTc in acute exacerbations of COPD requiring hospitalization. Int J Chron Obstruct Pulmon Dis. Jun 14,2018 ;13:1937-1947. doi: 10.2147/COPD.S157630. eCollection 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012773, encodeId=45492012e7327, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Sep 05 05:13:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795141, encodeId=8f9c1e95141e9, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri Dec 28 00:13:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488836, encodeId=c9bb148883679, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575032, encodeId=0ad615e503208, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338184, encodeId=8e1333818477, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Aug 12 19:34:08 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012773, encodeId=45492012e7327, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Sep 05 05:13:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795141, encodeId=8f9c1e95141e9, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri Dec 28 00:13:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488836, encodeId=c9bb148883679, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575032, encodeId=0ad615e503208, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338184, encodeId=8e1333818477, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Aug 12 19:34:08 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-12-28 日月
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012773, encodeId=45492012e7327, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Sep 05 05:13:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795141, encodeId=8f9c1e95141e9, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri Dec 28 00:13:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488836, encodeId=c9bb148883679, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575032, encodeId=0ad615e503208, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338184, encodeId=8e1333818477, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Aug 12 19:34:08 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-14 gous
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012773, encodeId=45492012e7327, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Sep 05 05:13:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795141, encodeId=8f9c1e95141e9, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri Dec 28 00:13:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488836, encodeId=c9bb148883679, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575032, encodeId=0ad615e503208, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338184, encodeId=8e1333818477, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Aug 12 19:34:08 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-14 fengyi817
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012773, encodeId=45492012e7327, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Sep 05 05:13:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795141, encodeId=8f9c1e95141e9, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri Dec 28 00:13:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488836, encodeId=c9bb148883679, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575032, encodeId=0ad615e503208, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Tue Aug 14 10:13:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338184, encodeId=8e1333818477, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Aug 12 19:34:08 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-12 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

Circulation:痛风患者使用别嘌呤醇与非布索坦的心血管安全性相似

高尿酸血症和痛风均会增加患者的心血管疾病(CVD)风险。目前,黄嘌呤氧化酶抑制剂(XOI)、别嘌呤醇和非布索坦是痛风患者进行降低尿酸治疗的主要药物,可对心血管风险产生不同的影响。

JACC:冠脉微血管功能不良可作为肥胖患者的心血管风险分层因子

除了体重指数(BMI)外,尚需要其他的因素来鉴别肥胖患者的心血管风险。本研究的目的旨在评估肥胖、冠脉微血管功能不良(CMD)和不良反应事件的相关性。本研究对827名心脏灌注正电子发射断层显像显示正常灌注的肥胖患者进行平均5.6年时间的随访,观察事件主要包括死亡、心梗或心衰住院。分析结果显示,BMI与冠脉血流储备(CFR)呈倒J型曲线相关,即在肥胖患者中,CFR随着BMI的升高而降低(p <

盘点:JACC8月第1期研究一览

1. 心衰患者左室射血分数的远期变化动态曲线DOI: 10.1016/j.jacc.2018.05.042http://www.onlinejacc.org/content/72/6/591心衰病人远期的左室射血分数(LVEF)变化曲线尚不清楚。本研究的目的旨在评估心衰伴左室射血分数降低(<40%)和中等范围LVEF(40%-49%)患者的LVEF随访15年的变化曲线。本研究纳入了1160例心

JACC:血浆二甲基精氨酸水平与房颤患者预后相关

一氧化氮(NO)理论上可以增加房颤患者血栓栓塞和出血的发生风险。本研究的目的旨在评估血浆甲基化精氨酸衍生物不对称和对称二甲基精氨酸(ADMA/SDMA)同时也是NO抑制剂与房颤患者预后的相关性。本研究纳入了ARISTOTLE临床试验中的5004名房颤患者,并取得了血浆样本,通过高效液相色谱法对其ADMA/SDMA水平进行了检测,平均随访时间是1.9年。分析结果显示,ADMA/SDMA水平随着患者年

中国高血压调查结果:心血管病医疗费用增速赶超GDP,移动医疗是契机?

在中国心脏大会2018(CHC2018)心血管社区防治论坛上,国家心血管病中心、阜外医院王增武教授把脉了我国最新的心血管病流行趋势,并介绍了我国当前的防治不完善之处和应对策略。

JACC:胸主动脉瘤的遗传基因筛选

胸主动脉瘤是呈进展性的,且有发生主动脉夹层的风险。有高达25%的胸主动脉瘤患者拥有可遗传的基因变异。本研究的目的旨在通过临床基因组资源(ClinGen)来精确地识别导致遗传性胸主动脉瘤和夹层(HTAAD)的基因。本研究通过半定量的ClinGen框架来评估53个候选基因与HTAAD的相关性。如果一个基因与孤立性胸主动脉瘤相关,并且能引起主动脉的治疗和家系的筛选,那么该基因被归为HTAAD致病基因。根